PharmAbcine Inc. Logo

PharmAbcine Inc.

Clinical-stage biotech developing human monoclonal antibodies for various diseases.

208340 | KO

Overview

Corporate Details

ISIN(s):
KR7208340000
LEI:
Country:
South Korea
Address:
대전광역시 유성구 유성대로1689번길 70 KT대덕2연구센터 연구2동 2층, 대전광역시

Description

PharmAbcine Inc. is a clinical-stage biotechnology company specializing in the development of fully human therapeutic monoclonal antibodies (mAbs). The company focuses on creating innovative treatments for diseases with high unmet medical needs, primarily in oncology, neovascular eye diseases, and other inflammatory and vascular disorders. Utilizing its proprietary human antibody library and discovery technologies, PharmAbcine advances a pipeline of next-generation IgG-based therapeutics. The company's mission is to contribute to human health by providing novel antibody-based drugs to patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-31 00:00
[기재정정]주주총회소집결의 (임시주주총회)
Korean 25.4 KB
2025-12-31 00:00
주주총회소집공고
Korean 140.4 KB
2025-12-17 00:00
투자판단관련주요경영사항(임상시험결과) (신생혈관성 연령관련 황반변성 환자를 대상으로 한 제1상 임상시험)
Korean 21.9 KB
2025-12-16 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.4 KB
2025-09-16 00:00
[기재정정]기타경영사항(자율공시) (상장폐지결정효력정지 가처분 신청)
Korean 12.1 KB
2025-08-19 00:00
투자판단관련주요경영사항 (PMC-309 독점실시권 라이선스 계약(기술이전 계약))
Korean 10.0 KB
2025-08-19 00:00
소송등의제기ㆍ신청(자율공시:일정금액미만의청구) (위약벌청구의 소)
Korean 8.7 KB
2025-08-14 00:00
[기재정정]사업보고서 (2024.12)
Korean 1.8 MB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 1.5 MB
2025-07-11 00:00
소송등의판결ㆍ결정 (위약벌청구의 소)
Korean 5.0 KB
2025-05-28 00:00
기타경영사항(자율공시) (상장폐지결정효력정지 가처분 신청)
Korean 6.3 KB
2025-05-28 00:00
주권매매거래정지 (투자자보호)
Korean 4.6 KB
2025-05-28 00:00
기타시장안내 (정리매매 보류 관련)
Korean 2.8 KB
2025-05-27 00:00
기타시장안내 (코스닥시장위원회 심의·의결 결과 및 상장폐지 결정)
Korean 3.3 KB
2025-05-27 00:00
주권매매거래정지해제 (상장폐지에 따른 정리매매 개시)
Korean 4.4 KB

Automate Your Workflow. Get a real-time feed of all PharmAbcine Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PharmAbcine Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PharmAbcine Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.